Abstract 5372: HER2 expression on tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer

2020 ◽  
Author(s):  
Afroditi Nanou ◽  
Leonie L. Zeune ◽  
Francois-Clement Bidard ◽  
Jean-Yves Pierga ◽  
Leon W. Terstappen
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Extracellular Vesicles ◽  
Metastatic Breast ◽  
Her2 Expression

scholarly journals HER2 expression on tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer

2020 ◽  
Vol 22 (1) ◽  
Author(s):  
Afroditi Nanou ◽  
Leonie Laura Zeune ◽  
Francois-Clement Bidard ◽  
Jean-Yves Pierga ◽  
Leonardus Wendelinus Mathias Marie Terstappen
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Extracellular Vesicles ◽  
Metastatic Breast ◽  
Her2 Expression

scholarly journals RNA Profiles of Circulating Tumor Cells and Extracellular Vesicles for Therapy Stratification of Metastatic Breast Cancer Patients

2018 ◽  
Vol 64 (7) ◽  
pp. 1054-1062 ◽  
Author(s):  
Corinna Keup ◽  
Pawel Mach ◽  
Bahriye Aktas ◽  
Mitra Tewes ◽  
Hans-Christian Kolberg ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Disease Progression ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Extracellular Vesicles ◽  
Therapy Monitoring ◽  
Quantitative Polymerase Chain Reaction ◽  
Metastatic Breast ◽  
Therapy Stratification

Abstract BACKGROUND Liquid biopsies are discussed to provide surrogate markers for therapy stratification and monitoring. We compared messenger RNA (mRNA) profiles of circulating tumor cells (CTCs) and extracellular vesicles (EVs) in patients with metastatic breast cancer (MBC) to estimate their utility in therapy management. METHODS Blood was collected from 35 hormone receptor-positive/HER2-negative patients with MBC at the time of disease progression and at 2 consecutive staging time points. CTCs were isolated from 5 mL of blood by positive immunomagnetic selection, and EVs from 4 mL of plasma by a membrane affinity-based procedure. mRNA was reverse transcribed, preamplified, and analyzed for 18 genes by multimarker quantitative polymerase chain reaction (qPCR) assays. RNA profiles were normalized to healthy donor controls (n = 20), and results were correlated with therapy outcome. RESULTS There were great differences in mRNA profiles of EVs and CTCs, with only 5% (21/403) of positive signals identical in both fractions. Transcripts involved in the PI3K signaling pathway were frequently overexpressed in CTCs, and AURKA, PARP1, and SRC signals appeared more often in EVs. Of all patients, 40% and 34% showed ERBB2 and ERBB3 signals, respectively, in CTCs, which was significantly associated with disease progression (P = 0.007). Whereas MTOR signals in CTCs significantly correlated with response (P = 0.046), signals in EVs indicated therapy failure (P = 0.011). The presence of AURKA signals in EVs seemed to be a marker for the indication of unsuccessful treatment of bone metastasis. CONCLUSIONS These results emphasize the potential of CTCs and EVs for therapy monitoring and the need for critical evaluation of the implementation of any liquid biopsy in clinical practice.

Sign in / Sign up

Export Citation Format

Share Document